Document is current
Any future updates will be listed below
-
Authors
Méndez, Constanza
Rodríguez-Guilarte, Linmar
Palacios, Pablo A.
Gutierrez-Vera, Cristian
Román, Francisca
Moreno-Tapia, Daniela
Ríos, Mariana
Reyes, Antonia
Cancino, Felipe A.
Otero, Francisco F.
Zurita, Constanza
Rivera, Daniela
Cabrera, Alex
Duarte, Luisa F.
Urzúa, Marcela
Iturriaga, Carolina
Rojas, Álvaro
Perez, Carlos M.
Redlich, Andrea Schilling
Fasce, Rodrigo A.
Fernández, Jorge
Mora, Judith
Ramírez, Eugenio
Domínguez, Angélica
Weiskopf, Daniela
Grifoni, Alba
Sette, Alessandro
Zeng, Gang
Meng, Weining
Goldbatt, David
Johnson, Marina
,
González-Aramundiz, José V.
Álvarez-Figueroa, María J.
Abarca, Katia
Carreño, Leandro J.
González, Pablo A.
Kalergis, Alexis M.
Peñaloza, Hernán F.
Bueno, Susan M.
-
Funding
Funding for this research was provided by:
Millennium Institute on Immunology and Immunotherapy (ICN09_016 / ICN 2021_045; former P09/016-F)
National Institute of Allergy and Infectious Diseases (75N9301900065)
Fondo de Innovación para la Competitividad (BIP Code: 30488811-0)
- License Information
-
More Information
Article History
Received: 23 April 2025
Accepted: 17 November 2025
First Online: 15 December 2025
Declarations
:
: The Institutional Scientific and Ethical Committee of Health Sciences at Pontificia Universidad Católica de Chile reviewed and approved the current study protocol (no. 220509011). The trial was approved by the Chilean Public Health Institute (ISP Chile) (no. 22623–22) and conducted according to the current ICH-GCP E6(R2) guidelines, the Declaration of Helsinki, and local regulations. Informed consent was obtained from all volunteers upon enrollment. Written informed consent was obtained from all participants prior to their enrollment in the study. Members of the CoronaVarCL study group are listed in the Additional file 1.
: Not applicable.
: GZ and WM are SINOVAC Biotech employees and contributed to the conceptualization of the study (clinical protocol and eCRF design) and did not participate in the analysis or interpretation of the data presented in the manuscript. A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna, AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. La Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest.
